C12Y 114/16001
Phenylalanine 4-monooxygenase
Official title: Phenylalanine 4-monooxygenase (1.14.16.1)
C12Y114/16001 (Phenylalanine 4-monooxygenase) appears on 43 US grants and 91 published applications in this corpus.
Search patents in C12Y- Granted patents
- 43
- Published applications
- 91
- Assignees
- 43
- Inventors
- 174
- Latest grant
- 10 Mar 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1990 | 1 | 0 |
| 1991 | 0 | 0 |
| 1992 | 0 | 0 |
| 1993 | 0 | 0 |
| 1994 | 0 | 0 |
| 1995 | 0 | 0 |
| 1996 | 0 | 0 |
| 1997 | 1 | 0 |
| 1998 | 0 | 0 |
| 1999 | 1 | 0 |
| 2000 | 1 | 0 |
| 2001 | 2 | 0 |
| 2002 | 0 | 1 |
| 2003 | 1 | 1 |
| 2004 | 0 | 1 |
| 2005 | 0 | 1 |
| 2006 | 0 | 0 |
| 2007 | 0 | 1 |
| 2008 | 0 | 0 |
| 2009 | 0 | 0 |
| 2010 | 0 | 0 |
| 2011 | 0 | 4 |
| 2012 | 0 | 1 |
| 2013 | 1 | 1 |
| 2014 | 0 | 0 |
| 2015 | 0 | 1 |
| 2016 | 5 | 4 |
| 2017 | 0 | 5 |
| 2018 | 2 | 4 |
| 2019 | 5 | 7 |
| 2020 | 3 | 11 |
| 2021 | 2 | 8 |
| 2022 | 2 | 10 |
| 2023 | 2 | 8 |
| 2024 | 9 | 9 |
| 2025 | 3 | 8 |
| 2026 | 2 | 5 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Recent patents
- Gene therapy for treating phenylketonuria10 Mar 2026US 12,569,525 B2The Trustees of the University of Pennsylvania
- PAH-modulating compositions and methods10 Feb 2026US 12,544,458 B2Flagship Pioneering Innovations VI, LLC
- MRNA therapy for phenylketonuria30 Dec 2025US 12,509,666 B2Translate Bio, Inc.
- Non-viral DNA vectors and uses thereof for expressing phenylalanine hydroxylase (PAH) therapeutics16 Sep 2025US 12,415,002 B2Generation Bio Co.
- Adeno-associated virus compositions for restoring PAH gene function and methods of use thereof21 Jan 2025US 12,203,094 B2Homology Medicines, Inc.
- Gene therapy for treating phenylketonuria6 Aug 2026US 2026/0224650 A1The Trustees of the University of Pennsylvania
- Compositions and methods for integration of viral vectors30 Jul 2026US 2026/0218237 A1Poseida Therapeutics, Inc.
- Optimized PAH gene and expression cassette and use thereof25 Jun 2026US 2026/0174901 A1Suzhou Nggt Biotechnology Co., Ltd.
- Messenger rna with heterologous untranslated regions for enhanced expression and uses thereof25 Jun 2026US 2026/0176597 A1Development Center for Biotechnology
- Mrna therapy for phenylketonuria18 Jun 2026US 2026/0167944 A1Translate Bio, Inc.
Most cited
By later US patents
- Hybrid molecules having translocation region and cell-binding region126US 5,668,255 ASeragen, Inc. · 1997
- Hybrid molecules having translocation region and cell-binding region85US 6,022,950 ASeragen, Inc. · 2000
- Recombinant DNAS encoding three-part hybrid proteins44US 5,965,406 ASeragen, Inc. · 1999
- MRNA therapy for phenylketonuria37US 9,522,176 B2Shire Human Genetic Therapies, Inc. · 2016
- Methods for the identification of mutations in the human phenylalanine hydroxylase gene using DNA probes34US 4,965,190 AHoward Hughes Medical Institute · 1990